MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
MyoKardia, Inc. (MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry. Cynthia Ladd, who has been leading MyoKardia’s legal function as General Counsel since January 2018, will be retiring this year.
MyoKardia ([[MYOK]] -0.8%) announces positive results from a Phase 2a clinical trial evaluating danicamtiv in stable heart failure patients with reduced ejection fraction. The data were presented virtually at the European Society of Cardiology's Heart Failure Association Discoveries event.Treatment for seven days showed that danicamtiv was generally well-tolerated and was...
MyoKardia, Inc. (MYOK) today announced the presentation and publication of positive data from the company’s Phase 2a clinical trial of danicamtiv (formerly MYK-491) along with nonclinical data elucidating danicamtiv’s novel mechanism of action. Results from both the clinical and nonclinical studies of danicamtiv were featured at the European Society of Cardiology’s Heart Failure Association (HFA) Discoveries online event and published simultaneously in the European Journal of Heart Failure.